P053 | CAS#2748196-63-4 | Ceramide synthase inhibitor

MedKoo Cat#: 463756 | Name: P053

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

P053 is a the first isoform-specific ceramide synthase inhibitor.

Chemical Structure

P053

CAS#2748196-63-4

Theoretical Analysis

MedKoo Cat#: 463756

Name: P053

CAS#: 2748196-63-4

Chemical Formula: C18H21Cl2NO2

Exact Mass: 353.0949

Molecular Weight: 354.27

Elemental Analysis: C, 61.03; H, 5.98; Cl, 20.01; N, 3.95; O, 9.03

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 450.00	2 Weeks
5mg	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

P053; P 053; P-053;

IUPAC/Chemical Name

(R)-2-amino-4-(4-((3,4-dichlorobenzyl)oxy)phenyl)-2-methylbutan-1-ol

InChi Key

ZQQHXJCIFGMUPY-GOSISDBHSA-N

InChi Code

InChI=1S/C18H21Cl2NO2/c1-18(21,12-22)9-8-13-2-5-15(6-3-13)23-11-14-4-7-16(19)17(20)10-14/h2-7,10,22H,8-9,11-12,21H2,1H3/t18-/m1/s1

SMILES Code

OC[C@](C)(N)CCC1=CC=C(OCC2=CC=C(Cl)C(Cl)=C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

P053 is a potent, non-competitive and selective ceramide synthase 1 (CerS1) inhibitor wirh an IC50 of 0.5 μM.

In vitro activity:

In a live-cell ceramide synthase assay using cortical neuron cultures, a two hour pre-treatment with P053 resulted in dose-dependent inhibition of de novo C18:0 ceramide synthesis from deuterated dihydrosphingosine (Fig. 2a), confirming that the drug is cell permeable and inhibits CerS1 activity in living cells. Reference: Nat Commun. 2018 Aug 21;9(1):3165. https://pubmed.ncbi.nlm.nih.gov/30131496/

In vivo activity:

As C18 is the dominant ceramide in SkM, P053 treatment reduced total ceramide content in this organ (Fig. 3f; P = 0.73 for effect of diet, P < 0.001 for effect of P053 by 2-way ANOVA). Very long chain ceramides (C22:0, C24:0 and C24:1) were significantly increased by P053 treatment in the HFD group (Fig. 3d, e), as was 42:2 SM, which is assumed to be the 18:1/24:1 (C24:1) form (Fig. 3g). Mean levels of 36:1 SM, which is derived from C18:0 ceramide, were 13% lower in P053-treated compared to vehicle-treated mice on both diets (Fig. 3g), however this effect was not statistically significant. Reference: Nat Commun. 2018 Aug 21;9(1):3165. https://pubmed.ncbi.nlm.nih.gov/30131496/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	84.68
	DMSO	65.0	183.48
	Ethanol	30.0	84.68

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 354.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Turner N, Lim XY, Toop HD, Osborne B, Brandon AE, Taylor EN, Fiveash CE, Govindaraju H, Teo JD, McEwen HP, Couttas TA, Butler SM, Das A, Kowalski GM, Bruce CR, Hoehn KL, Fath T, Schmitz-Peiffer C, Cooney GJ, Montgomery MK, Morris JC, Don AS. A selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolism. Nat Commun. 2018 Aug 21;9(1):3165. doi: 10.1038/s41467-018-05613-7. PMID: 30131496; PMCID: PMC6104039.

In vitro protocol:

In vivo protocol:

1: Turner N, Lim XY, Toop HD, Osborne B, Brandon AE, Taylor EN, Fiveash CE, Govindaraju H, Teo JD, McEwen HP, Couttas TA, Butler SM, Das A, Kowalski GM, Bruce CR, Hoehn KL, Fath T, Schmitz-Peiffer C, Cooney GJ, Montgomery MK, Morris JC, Don AS. A selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolism. Nat Commun. 2018 Aug 21;9(1):3165. doi: 10.1038/s41467-018-05613-7. PMID: 30131496; PMCID: PMC6104039.